FDG-PET/CT for diagnosis of primary ovarian cancer
BACKGROUND AND AIMTo evaluate the diagnostic value of integrated F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT) to discriminate malignant from benign ovarian tumors. METHODSOne hundred and eight women suspected of having ovarian cancer underwent preoperative...
Gespeichert in:
| Veröffentlicht in: | Nuclear medicine communications 2011-07, Vol.32 (7), p.549-553 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 553 |
|---|---|
| container_issue | 7 |
| container_start_page | 549 |
| container_title | Nuclear medicine communications |
| container_volume | 32 |
| creator | Kitajima, Kazuhiro Suzuki, Kayo Senda, Michio Kita, Masato Nakamoto, Yuji Onishi, Yumiko Maeda, Tetsuo Yoshikawa, Takeshi Ohno, Yoshiharu Sugimura, Kazuro |
| description | BACKGROUND AND AIMTo evaluate the diagnostic value of integrated F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT) to discriminate malignant from benign ovarian tumors.
METHODSOne hundred and eight women suspected of having ovarian cancer underwent preoperative FDG-PET/CT scans. FDG uptake was quantified by calculating the maximum standardized uptake value (SUVmax) of each tumor. The receiver operating characteristic curve was drawn to determine the optimal cut-off values of SUVmax that would best discriminate between benign and malignant tumors. Histopathologic results served as the reference standard. We assessed the association between SUVmax and with International Federation of Gynecology and Obsterics stage in borderline and malignant tumors, using one-factor analysis of variance and an unpaired t test with Bonferoni correction.
RESULTSThe SUVmax of benign (n=26), borderline (n=12) and malignant (n=73) lesions was 2.00±1.02, 2.72±1.04, and 7.55±4.29, respectively. Although there were significant differences between benign and malignant, and borderline and malignant lesions (P |
| doi_str_mv | 10.1097/MNM.0b013e328345b339 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_871005108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>871005108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4219-cfe0cf3baa105823a31b967dbb6cbaf5283abc6475e4030b49bb3fa7a01b04443</originalsourceid><addsrcrecordid>eNp9kDFPwzAQhS0EoqXwDxDKxpT2nHPiZESlLUgtMJTZsl2bBtK42AkV_56gFgYGhtMt77179xFySWFIoeCjxcNiCAooGkxyZKlCLI5InzKOcZol-THpA2UYY4ZZj5yF8AoAOWb8lPQSyoB30yfJ9HYWP02Wo_Eyss5Hq1K-1C6UIXI22vpyI_1n5D6kL2UdaVlr48_JiZVVMBeHPSDP08lyfBfPH2f345t5rFlCi1hbA9qikpJCmicokaoi4yulMq2kTbvSUumM8dQwQFCsUAqt5BKoAsYYDsj1Pnfr3XtrQiM2ZdCmqmRtXBtEzilASrufBoTtldq7ELyx4tBcUBDfsEQHS_yF1dmuDgdatTGrX9MPnU6Q7wU7VzXGh7eq3Rkv1kZWzfr_7C9N1XXi</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>871005108</pqid></control><display><type>article</type><title>FDG-PET/CT for diagnosis of primary ovarian cancer</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Kitajima, Kazuhiro ; Suzuki, Kayo ; Senda, Michio ; Kita, Masato ; Nakamoto, Yuji ; Onishi, Yumiko ; Maeda, Tetsuo ; Yoshikawa, Takeshi ; Ohno, Yoshiharu ; Sugimura, Kazuro</creator><creatorcontrib>Kitajima, Kazuhiro ; Suzuki, Kayo ; Senda, Michio ; Kita, Masato ; Nakamoto, Yuji ; Onishi, Yumiko ; Maeda, Tetsuo ; Yoshikawa, Takeshi ; Ohno, Yoshiharu ; Sugimura, Kazuro</creatorcontrib><description>BACKGROUND AND AIMTo evaluate the diagnostic value of integrated F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT) to discriminate malignant from benign ovarian tumors.
METHODSOne hundred and eight women suspected of having ovarian cancer underwent preoperative FDG-PET/CT scans. FDG uptake was quantified by calculating the maximum standardized uptake value (SUVmax) of each tumor. The receiver operating characteristic curve was drawn to determine the optimal cut-off values of SUVmax that would best discriminate between benign and malignant tumors. Histopathologic results served as the reference standard. We assessed the association between SUVmax and with International Federation of Gynecology and Obsterics stage in borderline and malignant tumors, using one-factor analysis of variance and an unpaired t test with Bonferoni correction.
RESULTSThe SUVmax of benign (n=26), borderline (n=12) and malignant (n=73) lesions was 2.00±1.02, 2.72±1.04, and 7.55±4.29, respectively. Although there were significant differences between benign and malignant, and borderline and malignant lesions (P<0.0001), there was no significant difference between benign and borderline lesions. Using an SUVmax cutoff of 2.55, the sensitivity, specificity and accuracy of FDG-PET/CT scanning to detect malignant or borderline tumors were 82.4, 76.9, and 81.1%, respectively. The SUVmax of stage I (n=35), stage II (n=8), stage III (n=34) and stage IV (n=8) was 3.59±2.32, 5.18±1.34, 8.72±2.69, and 15.05±3.77, respectively, and significant differences were observed between SUVmax values and the various International Federation of Gynecology and Obsterics stage (P<0.0001).
CONCLUSIONFDG-PET/CT scanning has a high diagnostic value in differentiating between malignant and benign tumors, and a low diagnostic value in differentiating between borderline and benign tumors.</description><identifier>ISSN: 0143-3636</identifier><identifier>EISSN: 1473-5628</identifier><identifier>DOI: 10.1097/MNM.0b013e328345b339</identifier><identifier>PMID: 21407140</identifier><language>eng</language><publisher>England: Lippincott Williams & Wilkins, Inc</publisher><subject>Adult ; Aged ; Female ; Fluorodeoxyglucose F18 ; Humans ; Middle Aged ; Ovarian Neoplasms - diagnostic imaging ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Positron-Emission Tomography ; Retrospective Studies ; ROC Curve ; Tomography, X-Ray Computed</subject><ispartof>Nuclear medicine communications, 2011-07, Vol.32 (7), p.549-553</ispartof><rights>2011 Lippincott Williams & Wilkins, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4219-cfe0cf3baa105823a31b967dbb6cbaf5283abc6475e4030b49bb3fa7a01b04443</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27926,27927</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21407140$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kitajima, Kazuhiro</creatorcontrib><creatorcontrib>Suzuki, Kayo</creatorcontrib><creatorcontrib>Senda, Michio</creatorcontrib><creatorcontrib>Kita, Masato</creatorcontrib><creatorcontrib>Nakamoto, Yuji</creatorcontrib><creatorcontrib>Onishi, Yumiko</creatorcontrib><creatorcontrib>Maeda, Tetsuo</creatorcontrib><creatorcontrib>Yoshikawa, Takeshi</creatorcontrib><creatorcontrib>Ohno, Yoshiharu</creatorcontrib><creatorcontrib>Sugimura, Kazuro</creatorcontrib><title>FDG-PET/CT for diagnosis of primary ovarian cancer</title><title>Nuclear medicine communications</title><addtitle>Nucl Med Commun</addtitle><description>BACKGROUND AND AIMTo evaluate the diagnostic value of integrated F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT) to discriminate malignant from benign ovarian tumors.
METHODSOne hundred and eight women suspected of having ovarian cancer underwent preoperative FDG-PET/CT scans. FDG uptake was quantified by calculating the maximum standardized uptake value (SUVmax) of each tumor. The receiver operating characteristic curve was drawn to determine the optimal cut-off values of SUVmax that would best discriminate between benign and malignant tumors. Histopathologic results served as the reference standard. We assessed the association between SUVmax and with International Federation of Gynecology and Obsterics stage in borderline and malignant tumors, using one-factor analysis of variance and an unpaired t test with Bonferoni correction.
RESULTSThe SUVmax of benign (n=26), borderline (n=12) and malignant (n=73) lesions was 2.00±1.02, 2.72±1.04, and 7.55±4.29, respectively. Although there were significant differences between benign and malignant, and borderline and malignant lesions (P<0.0001), there was no significant difference between benign and borderline lesions. Using an SUVmax cutoff of 2.55, the sensitivity, specificity and accuracy of FDG-PET/CT scanning to detect malignant or borderline tumors were 82.4, 76.9, and 81.1%, respectively. The SUVmax of stage I (n=35), stage II (n=8), stage III (n=34) and stage IV (n=8) was 3.59±2.32, 5.18±1.34, 8.72±2.69, and 15.05±3.77, respectively, and significant differences were observed between SUVmax values and the various International Federation of Gynecology and Obsterics stage (P<0.0001).
CONCLUSIONFDG-PET/CT scanning has a high diagnostic value in differentiating between malignant and benign tumors, and a low diagnostic value in differentiating between borderline and benign tumors.</description><subject>Adult</subject><subject>Aged</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Ovarian Neoplasms - diagnostic imaging</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Positron-Emission Tomography</subject><subject>Retrospective Studies</subject><subject>ROC Curve</subject><subject>Tomography, X-Ray Computed</subject><issn>0143-3636</issn><issn>1473-5628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kDFPwzAQhS0EoqXwDxDKxpT2nHPiZESlLUgtMJTZsl2bBtK42AkV_56gFgYGhtMt77179xFySWFIoeCjxcNiCAooGkxyZKlCLI5InzKOcZol-THpA2UYY4ZZj5yF8AoAOWb8lPQSyoB30yfJ9HYWP02Wo_Eyss5Hq1K-1C6UIXI22vpyI_1n5D6kL2UdaVlr48_JiZVVMBeHPSDP08lyfBfPH2f345t5rFlCi1hbA9qikpJCmicokaoi4yulMq2kTbvSUumM8dQwQFCsUAqt5BKoAsYYDsj1Pnfr3XtrQiM2ZdCmqmRtXBtEzilASrufBoTtldq7ELyx4tBcUBDfsEQHS_yF1dmuDgdatTGrX9MPnU6Q7wU7VzXGh7eq3Rkv1kZWzfr_7C9N1XXi</recordid><startdate>201107</startdate><enddate>201107</enddate><creator>Kitajima, Kazuhiro</creator><creator>Suzuki, Kayo</creator><creator>Senda, Michio</creator><creator>Kita, Masato</creator><creator>Nakamoto, Yuji</creator><creator>Onishi, Yumiko</creator><creator>Maeda, Tetsuo</creator><creator>Yoshikawa, Takeshi</creator><creator>Ohno, Yoshiharu</creator><creator>Sugimura, Kazuro</creator><general>Lippincott Williams & Wilkins, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201107</creationdate><title>FDG-PET/CT for diagnosis of primary ovarian cancer</title><author>Kitajima, Kazuhiro ; Suzuki, Kayo ; Senda, Michio ; Kita, Masato ; Nakamoto, Yuji ; Onishi, Yumiko ; Maeda, Tetsuo ; Yoshikawa, Takeshi ; Ohno, Yoshiharu ; Sugimura, Kazuro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4219-cfe0cf3baa105823a31b967dbb6cbaf5283abc6475e4030b49bb3fa7a01b04443</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Ovarian Neoplasms - diagnostic imaging</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Positron-Emission Tomography</topic><topic>Retrospective Studies</topic><topic>ROC Curve</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kitajima, Kazuhiro</creatorcontrib><creatorcontrib>Suzuki, Kayo</creatorcontrib><creatorcontrib>Senda, Michio</creatorcontrib><creatorcontrib>Kita, Masato</creatorcontrib><creatorcontrib>Nakamoto, Yuji</creatorcontrib><creatorcontrib>Onishi, Yumiko</creatorcontrib><creatorcontrib>Maeda, Tetsuo</creatorcontrib><creatorcontrib>Yoshikawa, Takeshi</creatorcontrib><creatorcontrib>Ohno, Yoshiharu</creatorcontrib><creatorcontrib>Sugimura, Kazuro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Nuclear medicine communications</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kitajima, Kazuhiro</au><au>Suzuki, Kayo</au><au>Senda, Michio</au><au>Kita, Masato</au><au>Nakamoto, Yuji</au><au>Onishi, Yumiko</au><au>Maeda, Tetsuo</au><au>Yoshikawa, Takeshi</au><au>Ohno, Yoshiharu</au><au>Sugimura, Kazuro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>FDG-PET/CT for diagnosis of primary ovarian cancer</atitle><jtitle>Nuclear medicine communications</jtitle><addtitle>Nucl Med Commun</addtitle><date>2011-07</date><risdate>2011</risdate><volume>32</volume><issue>7</issue><spage>549</spage><epage>553</epage><pages>549-553</pages><issn>0143-3636</issn><eissn>1473-5628</eissn><abstract>BACKGROUND AND AIMTo evaluate the diagnostic value of integrated F-fluorodeoxyglucose (FDG) positron emission tomography and computed tomography (PET/CT) to discriminate malignant from benign ovarian tumors.
METHODSOne hundred and eight women suspected of having ovarian cancer underwent preoperative FDG-PET/CT scans. FDG uptake was quantified by calculating the maximum standardized uptake value (SUVmax) of each tumor. The receiver operating characteristic curve was drawn to determine the optimal cut-off values of SUVmax that would best discriminate between benign and malignant tumors. Histopathologic results served as the reference standard. We assessed the association between SUVmax and with International Federation of Gynecology and Obsterics stage in borderline and malignant tumors, using one-factor analysis of variance and an unpaired t test with Bonferoni correction.
RESULTSThe SUVmax of benign (n=26), borderline (n=12) and malignant (n=73) lesions was 2.00±1.02, 2.72±1.04, and 7.55±4.29, respectively. Although there were significant differences between benign and malignant, and borderline and malignant lesions (P<0.0001), there was no significant difference between benign and borderline lesions. Using an SUVmax cutoff of 2.55, the sensitivity, specificity and accuracy of FDG-PET/CT scanning to detect malignant or borderline tumors were 82.4, 76.9, and 81.1%, respectively. The SUVmax of stage I (n=35), stage II (n=8), stage III (n=34) and stage IV (n=8) was 3.59±2.32, 5.18±1.34, 8.72±2.69, and 15.05±3.77, respectively, and significant differences were observed between SUVmax values and the various International Federation of Gynecology and Obsterics stage (P<0.0001).
CONCLUSIONFDG-PET/CT scanning has a high diagnostic value in differentiating between malignant and benign tumors, and a low diagnostic value in differentiating between borderline and benign tumors.</abstract><cop>England</cop><pub>Lippincott Williams & Wilkins, Inc</pub><pmid>21407140</pmid><doi>10.1097/MNM.0b013e328345b339</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0143-3636 |
| ispartof | Nuclear medicine communications, 2011-07, Vol.32 (7), p.549-553 |
| issn | 0143-3636 1473-5628 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_871005108 |
| source | MEDLINE; Journals@Ovid Complete |
| subjects | Adult Aged Female Fluorodeoxyglucose F18 Humans Middle Aged Ovarian Neoplasms - diagnostic imaging Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Positron-Emission Tomography Retrospective Studies ROC Curve Tomography, X-Ray Computed |
| title | FDG-PET/CT for diagnosis of primary ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-17T19%3A58%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=FDG-PET/CT%20for%20diagnosis%20of%20primary%20ovarian%20cancer&rft.jtitle=Nuclear%20medicine%20communications&rft.au=Kitajima,%20Kazuhiro&rft.date=2011-07&rft.volume=32&rft.issue=7&rft.spage=549&rft.epage=553&rft.pages=549-553&rft.issn=0143-3636&rft.eissn=1473-5628&rft_id=info:doi/10.1097/MNM.0b013e328345b339&rft_dat=%3Cproquest_cross%3E871005108%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=871005108&rft_id=info:pmid/21407140&rfr_iscdi=true |